Beta

Renovorx, inc.RNXT.US Overview

US StockHealthcare
(No presentation for RNXT)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

RNXT AI Insights

RNXT Overall Performance

RNXT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RNXT Recent Performance

-3.45%

Renovorx, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

RNXT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check RNXT's Trend

RNXT Key Information

RNXT Valuation Metrics

RNXT Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Price of RNXT

RNXT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RNXT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
34.37
PB Ratio
7.12
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.88%
Net Margin
-994.48%
Revenue Growth (YoY)
2511.63%
Profit Growth (YoY)
1751.16%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
34.37
PB Ratio
7.12
Price-to-FCF
-
Gross Margin
70.88%
Net Margin
-994.48%
Revenue Growth (YoY)
2511.63%
Profit Growth (YoY)
1751.16%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
  • When is RNXT's latest earnings report released?

    The most recent financial report for Renovorx, inc. (RNXT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RNXT's short-term business performance and financial health. For the latest updates on RNXT's earnings releases, visit this page regularly.

  • What is the operating profit of RNXT?

    According to the latest financial report, Renovorx, inc. (RNXT) reported an Operating Profit of -3.52M with an Operating Margin of -1,479.83% this period, representing a decline of 33.81% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RNXT's revenue growth?

    In the latest financial report, Renovorx, inc. (RNXT) announced revenue of 238K, with a Year-Over-Year growth rate of 453.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does RNXT have?

    At the end of the period, Renovorx, inc. (RNXT) held Total Cash and Cash Equivalents of 7.02M, accounting for 0.87 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does RNXT go with three margins increasing?

    In the latest report, Renovorx, inc. (RNXT) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.2%%, operating margin of -1,479.83%%, and net margin of -1,235.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RNXT's profit trajectory and future growth potential.

  • Is RNXT's EPS continuing to grow?

    According to the past four quarterly reports, Renovorx, inc. (RNXT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RNXT?

    Renovorx, inc. (RNXT)'s Free Cash Flow (FCF) for the period is -3.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 23.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RNXT?

    The latest valuation data shows Renovorx, inc. (RNXT) has a Price-To-Earnings (PE) ratio of -4.32 and a Price/Earnings-To-Growth (PEG) ratio of -0.55. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.